Literature DB >> 31277821

Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.

Jingxuan Zhao1, Zhiyuan Zheng2, Xuesong Han2, Amy J Davidoff3, Matthew P Banegas4, Ashish Rai2, Ahmedin Jemal2, K Robin Yabroff2.   

Abstract

OBJECTIVES: To evaluate the relationship between cancer history and cost-related medication nonadherence (CRN) as well as cost-coping strategies, by health insurance coverage.
METHODS: We used the 2013 to 2016 National Health Interview Survey to identify adults aged 18 to 64 years with (n = 3599) and without (n = 56 909) a cancer history. Cost-related changes in medication use included (1) CRN, measured as skipping, taking less, or delaying medication because of cost, and (2) cost-coping strategies, measured as requesting lower cost medication or using alternative therapies to save money. Separate multivariable logistic regressions were used to calculate the adjusted odds ratios (AORs) of CRN and cost-coping strategies associated with cancer history, stratified by insurance.
RESULTS: Cancer survivors were more likely than adults without a cancer history to report CRN (AOR 1.26; 95% confidence interval [CI] 1.10-1.43) and cost-coping strategies (AOR 1.10; 95% CI 0.99-1.19). Among the privately insured, the difference in CRN by cancer history was the greatest among those enrolled in high-deductible health plans (HDHPs) without health savings accounts (HSAs) (AOR 1.78; 95% CI 1.30-2.44). Among adults with HDHP and HSA, cancer survivors were less likely to report cost-coping strategies (AOR 0.62; 95% CI 0.42-0.90). Regardless of cancer history, CRN and cost-coping strategies were the highest for those uninsured, enrolled in HDHP without HSA, and without prescription drug coverage under their health plan (all P<.001).
CONCLUSIONS: Cancer survivors are prone to CRN and more likely to use cost-coping strategies. Expanding options for health insurance coverage, use of HSAs for those with HDHP, and enhanced prescription drug coverage may effectively address CRN.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  National Health Interview Survey; cancer; cost-coping strategies; cost-related medication nonadherence; health insurance; health saving accounts; high-deductible health plan; medications; out-of-pocket costs

Year:  2019        PMID: 31277821     DOI: 10.1016/j.jval.2019.01.015

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  8 in total

1.  Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA.

Authors:  Bahaa Kazzi; Fumiko Chino; Brigitte Kazzi; Bhav Jain; Sibo Tian; Joseph A Paguio; J Seth Yao; Vinayak Muralidhar; Brandon A Mahal; Paul L Nguyen; Nina N Sanford; Edward Christopher Dee
Journal:  Support Care Cancer       Date:  2022-07-25       Impact factor: 3.359

2.  Cost-Related Medication Nonadherence and Patient Cost Responsibility for Rural and Urban Cancer Survivors.

Authors:  Courtney P Williams; Amy Davidoff; Michael T Halpern; Michelle Mollica; Kathleen Castro; Benjamin Allaire; Janet S de Moor
Journal:  JCO Oncol Pract       Date:  2022-08

3.  Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Shelley A Jazowski; Aaron N Winn; Ethan Basch; Nancy L Keating
Journal:  JAMA Health Forum       Date:  2021-05-28

4.  Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.

Authors:  Shelley A Jazowski; Lauren Wilson; Stacie B Dusetzina; S Yousuf Zafar; Leah L Zullig
Journal:  JAMA Netw Open       Date:  2022-06-01

5.  Mortality-to-incidence ratios by US Congressional District: Implications for epidemiologic, dissemination and implementation research, and public health policy.

Authors:  Jan M Eberth; Whitney E Zahnd; Swann Arp Adams; Daniela B Friedman; Stephanie B Wheeler; James R Hébert
Journal:  Prev Med       Date:  2019-11-01       Impact factor: 4.018

6.  Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients.

Authors:  Mukhtar Ahmad Dar; Richa Chauhan; Krishna Murti; Vinita Trivedi; Sameer Dhingra
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

7.  Social risk factors among individuals with a history of cancer during the COVID-19 pandemic.

Authors:  Cheryl Kelly; Larissa Lee White; Shauna Goldberg Scott; Heather Spencer Feigelson; Andrea N Burnett-Hartman
Journal:  J Cancer Surviv       Date:  2022-08-03       Impact factor: 4.062

8.  Impact of Cost-Related Medication Nonadherence on Economic Burdens, Productivity Loss, and Functional Abilities: Management of Cancer Survivors in Medicare.

Authors:  Z Kevin Lu; Xiaomo Xiong; Jacob Brown; Ashley Horras; Jing Yuan; Minghui Li
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.